Press Releases

Roswell Park Comprehensive Cancer Center is among 100 of the nation’s top health care systems, representing thousands of hospitals in communities across the U.S., that have come together with an urgent plea for all Americans: mask up, because wearing a facemask is our best chance at slowing the surging COVID-19 pandemic now.

A team from Roswell Park Comprehensive Cancer Center has detailed striking findings on the effectiveness of a previously untried combination of old and new drugs as treatment for recurrent ovarian cancer.

A team led by Subhamoy Dasgupta, PhD, has determined that prostate cancer tumors change their metabolism to produce more fats, which helps them spread to and survive within the bones.

Roswell Park Comprehensive Cancer Center Deputy Director Kunle Odunsi, MD, PhD, FRCOG, FACOG received recognition Saturday in honor of his work with the “lab family” of the late and well-known immunologist, Lloyd J. Old, MD.

Roswell Park Comprehensive Cancer Center and the Roswell Park Alliance Foundation are celebrating the 20th anniversary of the Herd About Buffalo public art program with a commemorative auction.

New research from a team at Roswell Park suggests that a drug widely prescribed to control blood pressure may improve patients’ response to cancer immunotherapy.

Nurses, physician assistants and nurse practitioners are an integral piece of Roswell Park Comprehensive Cancer Center’s mission. Day in and day out, they are central to the multidisciplinary and integrative approach that drives the care of each and every Roswell Park patient. Drs. Andrew Storer and Karen Sharrah have been newly appointed to critical leadership roles that will guide further growth in for this team of dedicated professionals.

Research led by a team from Roswell Park details a promising new strategy for overcoming immunotherapy treatment resistance by zeroing in on dendritic cells and enhancing their function as “accessory cells” supporting other immune cells.

Giving patients with relapsed or refractory mantle cell lymphoma (MCL) access to more treatment options, Roswell Park Comprehensive Cancer Center has been approved to administer the FDA-approved chimeric antigen receptor (CAR) T-cell therapy Tecartus. The immunotherapy drug is manufactured by Kite, a subsidiary of Gilead Sciences.